Document Detail


The future role of losartan.
MedLine Citation:
PMID:  8583483     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The past few decades have seen a remarkable development in the field of pharmacological therapy, one of the most notable examples being the treatment of arterial hypertension. Some of the early anti-hypertensive agents were relatively crude by today's standards, but gradually efficacy, tolerability, or both, of blood pressure-lowering (BP) drugs have been improved. It is presently possible to choose from a number of effective and well-tolerated compounds for the treatment of hypertension. The latest additions to the anti-hypertensive armamentarium are the angiotensin II receptor antagonists, the most advanced of these being losartan. It is perhaps most relevant to compare losartan to the angiotensin converting enzyme (ACE) inhibitors, another class of anti-hypertensive agents which acts mainly by interfering with the renin-angiotensin-aldosterone system (RAAS). Studies have shown that losartan lowers BP at least as effectively as ACE inhibitors. However, the side-effect profile of losartan is more favourable. In particular cough, a relatively common side-effect of ACE inhibitors, has been shown to be significantly less common during losartan treatment. This is probably because losartan does not interfere with bradykinin metabolism, unlike the ACE inhibitors. Regarding the reversal of left ventricular hypertrophy (LVH), a powerful risk indicator for cardiovascular disease, we have shown that losartan is more effective in this regard than treatment with the beta-blocker atenolol. It appears, based on these and other findings, that interference with the RAAS is particularly useful in causing reversal of the cardiovascular hypertrophic changes. The prognostic implications remain to be demonstrated, but it would be logical to expect a benefit from this effect. It was recently shown that polymorphism of the ACE gene is associated with increased risk of coronary heart disease even in the absence of conventional risk factors. If these findings are confirmed the interest in interfering with the RAAS as a therapeutic modality in hypertension would obviously be strengthened. It is not easy to predict the future role of any new therapeutic modality. The positive relation between efficacy and tolerability of losartan, as well as the fact that several observations suggest that interference with the RAAS could be favourable from a prognostic point of view, suggest that losartan may come to play an important role in the future treatment of hypertension.
Authors:
L Hansson
Related Documents :
16283593 - Adenylyl cyclase type v deletion increases basal left ventricular function and reduces ...
3013653 - Angiotensin-converting enzyme responses following enalapril in the sodium deficient rat.
2642533 - Psychosocial variables and hypertension: a new look at an old controversy.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Journal of human hypertension     Volume:  9 Suppl 5     ISSN:  0950-9240     ISO Abbreviation:  J Hum Hypertens     Publication Date:  1995 Nov 
Date Detail:
Created Date:  1996-03-20     Completed Date:  1996-03-20     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  8811625     Medline TA:  J Hum Hypertens     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  S55-8     Citation Subset:  IM    
Affiliation:
Department of Geriatrics, University of Uppsala, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II / antagonists & inhibitors*
Antihypertensive Agents / pharmacology,  therapeutic use*
Biphenyl Compounds / pharmacology,  therapeutic use*
Forecasting
Humans
Hypertension / drug therapy
Imidazoles / pharmacology,  therapeutic use*
Losartan
Receptors, Angiotensin / antagonists & inhibitors*
Renin-Angiotensin System / drug effects,  physiology
Tetrazoles / pharmacology,  therapeutic use*
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Imidazoles; 0/Receptors, Angiotensin; 0/Tetrazoles; 11128-99-7/Angiotensin II; 114798-26-4/Losartan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
Next Document:  Reaching parity for minority medical students: a possibility or a pipe dream?